Lymphoma, Non-Hodgkin: all 2,043 studies

Page 6 of 21. Open to participants first (309), then studies with results posted, then the rest; newest registration first within each.

• Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell LymphomaCompletedNCT02073097Phase 1/2Results posted
• Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell TransplantTerminatedNCT02065869Phase 1/2Results posted
• Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory LymphomaCompletedNCT02059239Phase 1/2Results posted
• A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCLCompletedNCT02055820Phase 1/2Results posted
• Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple MyelomaCompletedNCT02037256Not applicableResults posted
• Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ LymphomasCompletedNCT02030834Phase 2Results posted
• Meloxicam vs Placebo for MobilizationCompletedNCT02003625Phase 2Results posted
• A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's LymphomaCompletedNCT01998893Phase 2Results posted
• Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid MalignanciesTerminatedNCT01998035Phase 1/2Results posted
• Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.CompletedNCT01996865Phase 3Results posted
• Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHLCompletedNCT01994382Phase 1/2Results posted
• A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's LymphomaCompletedNCT01992653Phase 1/2Results posted
• MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for LymphomaCompletedNCT01987505Phase 3Results posted
• Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular LymphomaCompletedNCT01980654Phase 2Results posted
• Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell LymphomaCompletedNCT01979536Phase 2Results posted
• A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin LymphomaCompletedNCT01974440Phase 3Results posted
• Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin LymphomaTerminatedNCT01973062Phase 2Results posted
• Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for LymphomaCompletedNCT01969435Phase 2Results posted
• Chemotherapy for Relapsed Epstein Barr Virus Associated LymphomaTerminatedNCT01964755Phase 2Results posted
• Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD PreventionCompletedNCT01951885Phase 3Results posted
• A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell LymphomaCompletedNCT01950364Phase 1Results posted
• Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid MalignanciesTerminatedNCT01947140Phase 1/2Results posted
• Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)CompletedNCT01938001Phase 3Results posted
• Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid MalignanciesCompletedNCT01921387Phase 1/2Results posted
• Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid MalignanciesCompletedNCT01919619Phase 2Results posted
• Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell LymphomaCompletedNCT01909934Phase 4Results posted
• Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's LymphomaTerminatedNCT01889797Phase 2Results posted
• Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute LeukemiaTerminatedNCT01887587Phase 1Results posted
• A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin LymphomaCompletedNCT01882803Phase 2Results posted
• Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.CompletedNCT01878890Phase 1Results posted
• A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHLTerminatedNCT01874288Phase 1/2Results posted
• Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOPCompletedNCT01868035Phase 2Results posted
• Preventing Stem Cell Transplant Complications With a Blood Separator MachineCompletedNCT01866839Phase 1/2Results posted
• Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic LeukemiaCompletedNCT01865617Phase 1/2Results posted
• Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01839916Phase 2Results posted
• Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT01812005Phase 2Results posted
• Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasTerminatedNCT01805037Phase 1/2Results posted
• Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin LymphomaCompletedNCT01800838Phase 1Results posted
• A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin LymphomaCompletedNCT01796171Phase 1/2Results posted
• Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01789255Phase 2Results posted
• Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin LymphomaCompletedNCT01775475Phase 2Results posted
• Ipilimumab and Local Radiation for Selected Solid TumorsTerminatedNCT01769222Phase 1Results posted
• Unrelated Umbilical Cord Blood (UBC)TransplantationCompletedNCT01768845Not applicableResults posted
• Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic MalignanciesCompletedNCT01760655Phase 2Results posted
• Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLLCompletedNCT01754857Phase 2Results posted
• Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell LymphomaTerminatedNCT01738594Phase 1Results posted
• Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT01733238Phase 2Results posted
• Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasTerminatedNCT01732926Phase 3Results posted
• Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasTerminatedNCT01732913Phase 3Results posted
• A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3aCompletedNCT01724021Phase 3Results posted
• Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC TransplantCompletedNCT01720264Phase 2Results posted
• Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell LymphomaCompletedNCT01718691Phase 2Results posted
• Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ LymphomaActive, not recruitingNCT01703949Phase 2Results posted
• Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedNCT01701986Phase 1/2Results posted
• A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous PlerixaforCompletedNCT01696461Phase 2Results posted
• A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT01691898Phase 1/2Results posted
• Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHLCompletedNCT01686165Phase 2Results posted
• Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)CompletedNCT01685008Phase 2Results posted
• Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid MalignanciesTerminatedNCT01678443Phase 1Results posted
• Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.CompletedNCT01663714Phase 2Results posted
• Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T CellCompletedNCT01660607Phase 1/2Results posted
• Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's LymphomasCompletedNCT01660451Phase 2Results posted
• Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLLCompletedNCT01659255Phase 1Results posted
• A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase TherapyCompletedNCT01643408Phase 2Results posted
• A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins LymphomaCompletedNCT01614197Phase 1Results posted
• Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TARCompletedNCT01611298Not applicableResults posted
• Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell LymphomaCompletedNCT01606878Phase 1Results posted
• A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab TreatmentCompletedNCT01596621Phase 3Results posted
• An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaCompletedNCT01592370Phase 1/2Results posted
• PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard TreatmentTerminatedNCT01581541Phase 1Results posted
• A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)CompletedNCT01573000Phase 2Results posted
• Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine ConditioningCompletedNCT01572662Phase 2Results posted
• Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's LymphomaTerminatedNCT01549886Phase 2Results posted
• Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's LymphomaCompletedNCT01536561Phase 1Results posted
• A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched RelativesTerminatedNCT01532635Phase 2Results posted
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 2Results posted
• Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01527045Phase 2Results posted
• Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic LeukemiaCompletedNCT01500083Phase 3Results posted
• Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin LymphomaCompletedNCT01492088Phase 1/2Results posted
• IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's LymphomaCompletedNCT01491841Phase 1Results posted
• Safety and Tolerability of HSC835 in Patients With Hematological MalignanciesCompletedNCT01474681Phase 1/2Results posted
• Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin LymphomaCompletedNCT01466881Phase 2Results posted
• A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous RituximabCompletedNCT01461928Phase 3Results posted
• Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and EtoposideCompletedNCT01458366Phase 1/2Results posted
• A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin DiseaseCompletedNCT01458288Phase 2Results posted
• NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic LymphomaCompletedNCT01451515Phase 2Results posted
• High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell LymphomaTerminatedNCT01434472Phase 2Results posted
• Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesCompletedNCT01427881Phase 2Results posted
• A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01421667Phase 2Results posted
• Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell TransplantTerminatedNCT01419795Phase 2Results posted
• Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin LymphomaTerminatedNCT01408043Not applicableResults posted
• BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)CompletedNCT01403948Phase 1Results posted
• Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression LevelCompletedNCT01396070Phase 2Results posted
• A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological MalignanciesCompletedNCT01384513Phase 2Results posted
• Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular LymphomaCompletedNCT01381692Phase 1/2Results posted
• Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two StepsTerminatedNCT01350258Phase 1/2Results posted
• Phase I Study of OPB-51602 in Patients With Hematologic MalignanciesCompletedNCT01344876Phase 1Results posted
• Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin LymphomaCompletedNCT01336933Phase 2Results posted
• A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)CompletedNCT01332968Phase 3Results posted
• Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's LymphomasCompletedNCT01329900Phase 2Results posted

← Lymphoma, Non-Hodgkin overview